# Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors

> **NCT00848523** · PHASE2 · TERMINATED · sponsor: **Neurological Surgery, P.C.** · enrollment: 6 (actual)

## Conditions studied

- Recurrent Malignant Gliomas

## Interventions

- **DRUG:** Panobinostat

## Key facts

- **NCT ID:** NCT00848523
- **Lead sponsor:** Neurological Surgery, P.C.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** insufficient accrual
- **Last updated:** 2010-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00848523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00848523, "Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00848523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*